fda English news | fda, Latest News & Live Updates in English | English News (Latest English News) at Lokmattimes.com

100% Made-in-India including the active ingredientManufactured in US FDA and EU-approved facility in IndiaIndicated for the treatment of neuro disordersDelhi NCR (India), May 16: Biophore India Pharmaceuticals has announced that it has received CDSCO approval for manufacturing and marketing of Cannabidiol active ingredient in India and its subsidiary, Zenara Pharma, has received the approval for the final product, Cannabidiol Oral Solution 100mg/ml, for neuro disorders. This is the first time ever that a Cannabidiol-based product has been approved in India, delivering a unique therapy option. The product is being manufactured at US FDA and EU-approved state-of-the-art facilities in Hyderabad and Vishakapatnam.Cannabidiol has been developed by Zenara and Biophore completely from a synthetic route, and the same product has been filed with the US FDA as well and awaiting approval. The active ingredient has already been registered with the US FDA last yearDr. Jagadeesh Babu Rangisetty, CEO at Biophore, says, “The approval of this product is in line with our vision to bring world-class products to the Indian market. It has been an intense journey over the past few years on the development program of this product, both the active ingredient and the final product, and we are really excited to get the green light. We continue to invest in such first-of-its-kind products for the Indian market, and we will see more of such in the coming years.”The approval currently received is for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in patients 1 year of age or older. Cannabidiol is already approved in the US for these indications, and this approval in India is expected to bring global treatment options within reach of Indian patients.Dr Rangisetty adds, “It is the first time that such a product has been approved in the country, and we are proud to have played a part in it. The approval process during the last few months was exhaustive, and we thank the DCGI, CDSCO & Dr Vinod K Paul (Member, NITI Aayog) for their valuable inputs and collaboration. We are now preparing for the launch of this product by collaborating with a few like-minded organizations within India, including the largest manufacturer in the country, Akums Drugs & Pharmaceuticals Ltd.”Biophore has informed that they will soon be completing the collaboration agreements with Akums and other established corporates who are active in this segment and are targeting to launch the product in the next four monthsIf you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

FdaFOLLOW

Fda, Latest News

Mumbai (Maharashtra) [India], June 28 : Maharashtra Assembly Speaker Rahul Narvekar held a meeting with the DGP of Maharashtra ... ...

PNN New Delhi [India], June 24: The global arbutin market has grown significantly over the past few years due ... ...

New Delhi, June 13 US drugmaker Pfizers and British pharma major GSK are likely to face significant competition ... ...

New Delhi, June 7 The Alzheimer's disease market is projected to experience robust growth at a compound annual ... ...

BusinessWire India New Delhi [India], June 2: Revolutionising the beauty and skincare market in India, La Pink has introduced ... ...

PRNewswire Tampa (Florida) [US], May 29: The US FDA, on the 24th of May 2023, granted an Investigational Device ... ...

New York, May 20 US-based brain-computer interface developer Paradromics may be a step closer to getting the Food ... ...

100% Made-in-India including the active ingredient Manufactured in US FDA and EU-approved facility in India Indicated for the treatment of neuro disorders Delhi NCR (India), May ... ...